Paper9108427
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
Slattery JT and 27 others. Blood, 1997. Cited by 277 papers, by iCite.
Cite this record
ConductScience Library. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Papers, record 9108427. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9108427
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow Transplantation | Major topic |
| Busulfan | Major topic |
| Leukemia, Myeloid, Accelerated Phase | Major topic |
| Leukemia, Myeloid, Chronic-Phase | Major topic |
| Transplantation Conditioning | Major topic |
| Adult | |
| Cause of Death | |
| Cyclophosphamide | |
| Female | |
| Graft Rejection | |
| Graft vs Host Disease | |
| Humans | |
| Infections | |
| Male | |
| Middle Aged | |
| Neoplasm, Residual | |
| Quality of Life | |
| Recurrence | |
| Remission Induction | |
| Survival Analysis | |
| Transplantation, Homologous | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 15704 | NCI NIH HHS | United States | P01CA015704 | PubMed and NIH | NIH RePORTER |
| CA 18029 | NCI NIH HHS | United States | P01CA018029 | PubMed and NIH | NIH RePORTER |
| CA 18221 | NCI NIH HHS | United States | P01CA018221 | PubMed and NIH | NIH RePORTER |
| P30CA015704 | NIH | NIH RePORTER |
Cited by106
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 277 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42517921 | Development of a simplified population pharmacokinetic-pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment. | Cancer Chemother Pharmacol | 2026 | https://conductscience.org/library/papers/42517921 | PubMed |
| 40788512 | Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40788512 | PubMed |
| 37491812 | Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study. | CPT Pharmacometrics Syst Pharmacol | 2023 | https://conductscience.org/library/papers/37491812 | PubMed |
| 37379285 | Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. | Blood Adv | 2023 | https://conductscience.org/library/papers/37379285 | PubMed |
| 36820303 | Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/36820303 | PubMed |
| 36710948 | Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients. | Blood Cell Ther | 2022 | https://conductscience.org/library/papers/36710948 | PubMed |
| 35336021 | Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35336021 | PubMed |
| 34523110 | Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation. | Int J Hematol | 2021 | https://conductscience.org/library/papers/34523110 | PubMed |
| 33231122 | Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. | Leuk Lymphoma | 2021 | https://conductscience.org/library/papers/33231122 | PubMed |
| 32886279 | Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. | Int J Hematol | 2021 | https://conductscience.org/library/papers/32886279 | PubMed |
| 31851762 | Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. | Br J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/31851762 | PubMed |
| 31555969 | Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. | Int J Hematol | 2020 | https://conductscience.org/library/papers/31555969 | PubMed |
| 31467455 | Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. | J R Stat Soc Ser C Appl Stat | 2019 | https://conductscience.org/library/papers/31467455 | PubMed |
| 31326610 | Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different? | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/31326610 | PubMed |
| 31212080 | A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/31212080 | PubMed |
| 31160806 | Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. | Bone Marrow Transplant | 2019 | https://conductscience.org/library/papers/31160806 | PubMed |
| 31136799 | Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/31136799 | PubMed |
| 31089278 | Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study. | Bone Marrow Transplant | 2019 | https://conductscience.org/library/papers/31089278 | PubMed |
| 30532055 | Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. | Bone Marrow Transplant | 2019 | https://conductscience.org/library/papers/30532055 | PubMed |
| 29884851 | Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. | Bone Marrow Transplant | 2019 | https://conductscience.org/library/papers/29884851 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9108427
GET https://conductscience.org/api/papers/v1/9108427/authors?page=2